Slides and webcasts are available to registered delegates and ESMO Members.
Abstracts and ePosters are open access.
Results from the CodeBreaK 200 trial represent an improvement for a difficult-to-treat patient population
Results from the COSMIC-313 trial show that adding cabozantinib to nivolumab plus ipilimumab prolongs progression-free survival, but also increases toxicity
Results from the RADICALS-HD and PRESTO trials show encouraging metastasis-free and biochemical progression-free survival benefits with androgen deprivation therapy, but they are not practice-changing yet
Findings show overall survival benefits with front-line atezolizumab versus single-agent chemotherapy, but questions remain regarding who might benefit
In the OCLURANDOM trial, progression-free survival was longer in patients receiving lutetium-octreotate versus sunitinib